Shenzhen Cell Valley and Lu Daopei Medical Group to carry out in-depth cooperation
Recently, Dr. Shi Yuanyuan, Chairman of the Company, met with Ms. Zhao Yi, Chief Operating Officer of Lu Daopei Medical Group, Mr. CAI Peng, General Manager of Wuhan Daopei Placenta Stem Cell Biotechnology Co., LTD., and Professor Chen Junhui, Director of Interventional and Cell Therapy Center of Peking University Shenzhen Hospital, in Shenzhen. Lu Daopei Medical Group is a private medical group founded in 2012 by Academician Lu Daopei of the Chinese Academy of Engineering, a famous hematologist and hematopoietic stem cell transplantation expert, which focuses on the treatment, scientific research and teaching of hematological diseases and tumors. Lu Daopei medical team has carried out CAR-T clinical trial project since July 2015, with remarkable efficacy and high safety. As of December 2021, 1,479 patients have been enrolled in CAR-T clinical trials, and its excellent test results have been recognized and praised by the international hematology community.
During the meeting, the two sides closely focused on accelerating the development of cell therapy tumor technology in China, and conducted in-depth discussions on the establishment of cell immunotherapy such as CAR-T and CAR-NK, and the related clinical research, cell detection and scientific research platform construction of CAR-T cell immunotherapy. The two sides will carry out comprehensive and in-depth cooperation in the field of cell therapy.
Subsequently, Shenzhen Cell Valley Biomedicine Co., Ltd. and Wuhan Daopei Placenta Stem Cell Biotechnology Co., Ltd. and Hubei Stem Cell Bank signed the "CAR T cell Therapy clinical research Cooperation Framework Agreement".
Wuhan Daopei Placenta Stem Cell Biotechnology Co., Ltd. is a biotechnology company located in Hubei High-tech Development Zone founded by Academician Lu Daopei of Chinese Academy of Engineering in 2010, with Academician Lu Daopei as the legal representative.
In 2011, Hubei Provincial Science and Technology Department approved the establishment of Hubei Provincial stem Cell Bank relying on Wuhan Daopei Placenta Stem Cell Biotechnology Co., LTD. Mainly engaged in new stem cell drugs, cellular immunotherapy, stem cell preservation technology development, stem cell clinical transplantation application, stem cell isolation and preservation. To provide resources, technology and basic conditions platform support for stem cell research in the province.
Lu Daofai Medical Group has six specialized medical and scientific research institutions dedicated to the clinical exploration of the treatment of hematologic malignancies and the effectiveness and safety research of CAR-T clinical cell therapy technology, with a total effective rate of more than 90%. It is the single center medical institution with the largest number of CAR-T cases in China and one of the institutions with the largest clinical data in the world. In the international leading level.
During the meeting, the two sides closely focused on accelerating the development of cell therapy tumor technology in China, and conducted in-depth discussions on the establishment of cell immunotherapy such as CAR-T and CAR-NK, and the related clinical research, cell detection and scientific research platform construction of CAR-T cell immunotherapy. The two sides will carry out comprehensive and in-depth cooperation in the field of cell therapy.
Subsequently, Shenzhen Cell Valley Biomedicine Co., Ltd. and Wuhan Daopei Placenta Stem Cell Biotechnology Co., Ltd. and Hubei Stem Cell Bank signed the "CAR T cell Therapy clinical research Cooperation Framework Agreement".
Wuhan Daopei Placenta Stem Cell Biotechnology Co., Ltd. is a biotechnology company located in Hubei High-tech Development Zone founded by Academician Lu Daopei of Chinese Academy of Engineering in 2010, with Academician Lu Daopei as the legal representative.
In 2011, Hubei Provincial Science and Technology Department approved the establishment of Hubei Provincial stem Cell Bank relying on Wuhan Daopei Placenta Stem Cell Biotechnology Co., LTD. Mainly engaged in new stem cell drugs, cellular immunotherapy, stem cell preservation technology development, stem cell clinical transplantation application, stem cell isolation and preservation. To provide resources, technology and basic conditions platform support for stem cell research in the province.
Lu Daofai Medical Group has six specialized medical and scientific research institutions dedicated to the clinical exploration of the treatment of hematologic malignancies and the effectiveness and safety research of CAR-T clinical cell therapy technology, with a total effective rate of more than 90%. It is the single center medical institution with the largest number of CAR-T cases in China and one of the institutions with the largest clinical data in the world. In the international leading level.
